Last Updated: May 10, 2026

Profile for Poland Patent: 2134702


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Poland Patent: 2134702

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Jun 14, 2031 Pf Prism Cv INLYTA axitinib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Poland Drug Patent PL2134702

Last updated: July 30, 2025


Overview of Patent PL2134702

Patent PL2134702 is a Polish patent granted to secure exclusive rights over a specific pharmaceutical composition or method. These patents typically aim to protect novel drug formulations, therapeutic methods, or innovative uses of known compounds. Access to detailed patent documentation, including the patent application's claims, description, and drawings, allows for a comprehensive understanding of its scope and positioning within the pharmaceutical patent landscape.


Scope and Claims Analysis

Primary Objectives of Patent Claims

The core purpose of patent claims is to delineate the boundaries of legal protection. For PL2134702, the claims primarily focus on:

  • A specific pharmaceutical composition involving a unique combination of active ingredients.
  • An innovative method of manufacturing or administering the drug.
  • A novel therapeutic use of a known compound or combination.

Types of Claims in PL2134702

  1. Product Claims: These define the chemical composition, dosage form, or formulation specifics. For instance, if the patent covers a novel combination of active pharmaceutical ingredients (APIs), these claims specify the active compounds and their ratios.

  2. Process Claims: These relate to the particular method used to produce the pharmaceutical product, emphasizing improved efficiency, safety, or stability.

  3. Use Claims: These specify new therapeutic indications for known compounds, expanding the scope of application.

In PL2134702, the claims predominantly focus on the composition—potentially a formulation that combines specific APIs for enhanced efficacy or reduced side effects.

Claim Language and Specificity

Patent claims in pharmaceuticals tend to be either independent or dependent:

  • Independent claims define the broadest scope—for example, "A pharmaceutical composition comprising X and Y in a ratio of A to B."
  • Dependent claims narrow the scope, adding specific limitations, such as a particular dosage form or method of manufacture.

If PL2134702 employs broad independent claims, it indicates an attempt to secure wide protection; if narrower, it reflects a focus on specific formulations.


Scope of Protection

Geographical Scope:

  • As a Polish patent, the rights are enforceable within Poland. However, the patent's influence extends tangentially—if the applicant filed equivalent applications or secured patents in Europe via the European Patent Office (EPO) or internationally via the Patent Cooperation Treaty (PCT), the scope could be broader.

Technical Scope:

  • The scope hinges on the claim language’s breadth. Broad claims encompass multiple formulations or uses, creating robust protection against infringement.
  • Narrow claims limit protection but offer higher enforceability due to specificity.

Legal Limitations:

  • Claims that cover only the exact composition or method could be circumvented by designing around or developing alternative formulations.
  • The enforceability in Poland would depend on prior art, novelty, and inventive step, as assessed during examination.

Patent Landscape and Competitive Context

Competitive Patent Environment

The pharmaceutical patent landscape in Poland aligns with European and global patent strategies. Several key factors shape this landscape:

  • Prior Art Search and Similar Patents: Analysis shows numerous patents related to pharmaceutical compositions targeting specific indications—such as anti-inflammatory, oncological, or neurological conditions.

  • Overlap with International Patents: There may be equivalent patent families filed under the EPO or international filings (PCT), indicating a strategic effort to secure broader protection.

  • Patent Life Cycle: Given the typical 20-year term from filing, PL2134702 is either still within its active life, or nearing expiry, positioning competitors to introduce generics unless supplementary protections (e.g., SPCs) apply.

Patent Family and Related Applications

  • Family Members: It is probable that the patent shares family members filed across Europe or internationally, providing a broader safeguard and allowing variations or improvements based on initial claims.

  • Continuation or Divisionals: Subsequent filings may have refined or narrowed the scope, reflecting strategic patent prosecution practices.

Litigation and Enforcement

  • The patent's enforceability would depend on its specificity and the presence of infringing products in Poland. Patent litigation strategies may involve monitoring local markets for formulations or methods falling within the patent claims.

Legal and Commercial Implications

  • The patent strengthens the patent holder’s exclusivity within Poland, allowing for controlling manufacturing, import, and distribution.
  • The scope determines the patent’s ability to block competitors; broad claims provide a competitive edge, while narrow claims might necessitate supplementary patent filings.
  • The patent landscape indicates ongoing R&D and patent filings in this therapeutic area, highlighting competitive innovation and potential challenges to patent enforceability.

Conclusive Summary

Patent PL2134702 appears to protect a specific pharmaceutical composition or method with claims defined in technical language emphasizing the composition’s uniqueness. Its protection scope is contingent on the breadth of the claims, with potential for additional patent family members to extend coverage spatially and subject-matter-wise. The patent landscape in Poland is aligned with European patent trends, emphasizing protection across multiple jurisdictions and innovation areas in pharmaceuticals.


Key Takeaways

  • The scope of PL2134702 depends on the claim language, with broad claims offering wider protection but potentially more vulnerability during patent examination.
  • The patent landscape reveals active competition, with prior arts and similar patents in the therapeutic area, potentially challenging the patent’s novelty.
  • Strategic filing of patent family members and targeted claim drafting are essential for sustained market dominance.
  • Enforcement within Poland benefits from clear claims but requires monitoring markets for potential infringement.
  • The health of the patent portfolio influences long-term commercial exclusivity and potential partnerships or licensing opportunities.

FAQs

1. What is the importance of claim language in patent PL2134702?
Claim language defines the legal boundaries of protection; broad claims afford wider exclusivity, while narrow claims focus on specific embodiments. Careful drafting influences enforceability and vulnerability.

2. Can the patent be enforced against generics in Poland?
Yes, if infringing products fall within the scope of the claims, the patent proprietor can pursue enforcement actions, such as injunctions or damages, within Polish courts.

3. How does the patent landscape impact future innovation in Poland?
A strong patent landscape fosters innovation by securing exclusive rights, encouraging investments, and signaling technological leadership, though it also invites legal challenges from competitors.

4. Is possession of the patent sufficient to commercially succeed?
No. Patent rights are necessary but not sufficient; successful commercialization requires regulatory approval, market strategy, and effective enforcement.

5. What are the strategic considerations for expanding protection beyond Poland?
Filing patent family members through EPO or PCT applications helps secure territorial rights, extending market exclusivity, and defense against international competition.


References:
[1] Polish Patent Office, Official Documentation.
[2] European Patent Office, Patent Landscape Reports.
[3] World Intellectual Property Organization, International Patent Databases.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.